When scientists first sequenced the human genome in 2003, it cost more than one hundred million dollars. Now, with advancements in technology and the help of companies like Eric Lefkofsky’s Tempus the process costs around five thousand and is expected to become even less cost-prohibitive in the near future.
Tempus is looking to modernize cancer treatment by updating the infrastructure that stores and analyzes patient information both by making one’s genetic makeup commonly referenced in their care and by making data that was already traditionally collected more intelligible. A large portion of patient information is handwritten by doctors and other caregivers, by using Tempus’ optical character recognition technology, these notes can be turned into usable and searchable data.
The data that will be collected and used will not only revolutionize individual patient care, it could eventually lead to cures for different types of cancer as new data will be able to be examined from patients across the globe. By comparing instances of disease across the network, scientists and doctors may be able to find links between cancer cases. Additionally, by knowing a patient’s chemical makeup doctors will be able to better tailor a treatment plan for that person’s exact genetics.
Eric Lefkofsky is the former CEO and co-founder of groupon, he resigned from his position at CEO to chairman in November 2015. Lefkofsky obtained his Juris Doctor at University of Michigan Law School and is presently an adjunct professor at the University of Chicago with a course on creating technology based businesses. He previously taught a course on disruptive business models and technology at Northwest University as well as having published his book Accelerated Disruption through Easton Studio Press.
Tempus operates as part of Lightbank, a Chicago based company Eric Lefkofsky also co-founded. Lightbank is a venture capital firm that specializes in disruptive technology startups outside of Silicon Valley.
A research study carried out on Assisted Reproductive Technologies (AST) revealed that the method was not a major contributor of defects associated to birth. After an extensive study, the research revealed that there are other factors such as pre-fertile pregnancies and problems that occur during conception. Children born naturally were at lower risks of being defected as compared to those born through AST (https://www.researchgate.net/publication/275053697).
One of the most distressing things is being diagnosed with cancer. The idea of going through chemo therapy and other cancer treatment becomes more terrifying than the cancer itself. The side effects of these treatments become so severe that one might wish that they never started with the treatment. Check Oncotarget at scimagojr.com
Patients with a type of cancer called papillary thyroid carcinoma experience a tough situation since after some time of treating the disease with vemurafenib drug, it starts resisting it. As a result, a team of researchers from the Harvard School of Medicine has committed to finding a solution for the resistance. They have suggested the use of a drug (palbociclib) that has been approved in the treatment of breast cancer that has advanced. They recommend it as a solution for the resistance to vemurafenib. Learn more about Oncotarget at Eurekalert.org.
According to an interview done on one of the team members on the research findings which can also be found in Oncotarget’s podcast on iTunes, Stitcher and Player F.M, the research they carried out showed that treatment for thyroid cancer can be done by combining palbociclib and vemurafenib to overcome the resistance.
As cancer spread through cell division, the combined treatment was able to prevent the multiplication of the cells and it killed the cancer cells faster. This was after comparing how each drug acted on the cells which showed that their rate of killing the cancer cells was slow and thus combining them led to better results.
After carrying a deep research, the team is satisfied that the combined therapy can be used to treat the drug resistant thyroid cancer that has either primary or secondary drug resistance. The treatment has been proven by the researchers as ready to be taken to clinical level to be tried on patients.
Dr. Mark Holterman serves as a professor at the Illinois College of Medicine University since the year 2011. Amongst his roles is, he is an attending paediatric surgeon at the Children’s Hospital of Advocate Christ, the Illinois Children’s Hospital and St. Francis Hospital.
Mark is an individual who has maintained associations with many proficient organizations like the American Academy of Paediatrics and the American College of Surgeons. His specialization is in the field of paediatric surgery and his study interests are reformative medication, stem cell treatments as well as fatness and innovative treatments of cancer. Read more about Dr. Mark Holterman at Dial Dish.
Holterman went to the University of Yale majoring in biology. He later earned his PhD and MD from Virginia University. Afterwards, he successfully finished internship in universal surgery at the Virginia Health Sciences University and his communion in pediatric surgery at the Children’s Hospital and Medical Centre. Previously, Mark worked as a chief surgeon at Advocate Christ Children’s Hospital and as an attending paediatric surgeon at Rush University Medical Centre.
Dr. Mark Holterman helps children using his skilled surgical practices in two separate hospitals in Peoria. All over his career, Mark has devoted his entire self in the creation of supplementary fit choices for the young generation. He goes even further to create time to manage Mariam Global Health which focuses on the growth of therapies of the cells and to donate a part of his little time to groups like the International Pediatric Specialists Alliance for the Children living in Vietnam. Learn more about Dr. Mark Holterman’s profile at healthgrove.com.
This group was founded with the aim of helping enhance the lives of the younger generation in Vietnam. IPSAC-VN’s biggest program was the International Academic Program that aimed at providing training activities for doctors from Vietnam in the United States.
Mark Holterman has been and continues to be a necessary element in the numerous initiatives carried out by the organization that render workers, medical provisions and other resources needed by the region. Mark Holterman’s determination is to get treatments to continuing illnesses that affect children. His partnership with the Children’s Hospital Los Angeles enabled them to launch a new program known as Camp PowerUp.
Clay Siegall is CEO and founder of biotech giant Seattle Genetics. Since 1998, Dr. Siegall has led the company with strong leadership and a solid vision, taking the company to the top of the biotech and cancer drug development industry.
Dr. Siegall first became interested in cancer research while attending his graduate studies at the University of Maryland. While pursuing a degree in zoology, Dr. Siegall had a family member who fell sick with cancer. During this ordeal, the family member nearly lost their life. This was not due to the cancer itself. Instead, it was due to the brutal regimen of chemotherapy that was the reigning model for cancer treatment at that time. The family member developed severe anemia and nearly died from shock.
This prompted Dr. Clay Siegall to realize that the state of cancer treatment at that time was far from ideal. This imparted an intense interest in pursuing a career in cancer research and hopefully someday contributing to new treatment models that were not so deadly and ridden with terrible side effects.
Dr. Siegall decided to pursue a degree in genetics. In 1988 he received his doctorate in genetics from George Washington University. Shortly thereafter he was hired by the National Cancer Institute as a junior researcher. There, he worked on an exciting new area of cancer research called targeted cancer therapies. This was a new field of drug development that promised to allow for therapies that would specifically target the tumor site, rather than releasing highly toxic drugs into the bloodstream.
After working for the National Cancer Institute for around four years, Dr. Siegall was hired by Bristol-Myers Squibb as a senior researcher. It was at Bristol-Myers Squibb that he first started working on a revolutionary new type of targeted cancer therapy called antibody drug conjugates. Antibody drug conjugates are a drug class that uses elements of the patient’s immune system to deliver highly toxic chemicals directly to the site of the tumor without any systemic release of the agent into the bloodstream. This dramatically increases the amount of drugs that can be given at any given time. The increased so-called therapeutic window enables oncologists to administer highly lethal doses, leading to much more effective treatments and shorter durations of treatment courses.